Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...

By David Lawder, David Milliken and Andrea Shalal WASHINGTON (Reuters) -International finance chiefs are returning home with a measure of relief over the surprising resilience of the ...

Amid economic uncertainties, it is important to balance the joy of celebrations with long-term financial security. Rather ...